Aptose Biosciences
Biotechnology, High BLF Dr, San Diego, , 92130, California, 12770, United States, 11-50 Employees
Who is APTOSE BIOSCIENCES
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. ...
Read More
-
Headquarters: 12770 High BLF Dr, San Diego, California, 92130, United States
-
Date Founded: 2014
-
Employees: 11-50
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
-
CEO:
Diane Greger
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from APTOSE BIOSCIENCES
Aptose Biosciences Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aptose Biosciences
Answer: Aptose Biosciences's headquarters are located at High BLF Dr, San Diego, , 92130, California, 12770, United States
Answer: Aptose Biosciences's official website is https://aptose.com
Answer: Aptose Biosciences's revenue is $25 Million to $50 Million
Answer: Aptose Biosciences's SIC: 2836
Answer: Aptose Biosciences's NAICS: 541715
Answer: Aptose Biosciences has 11-50 employees
Answer: Aptose Biosciences is in Biotechnology
Answer: Aptose Biosciences contact info: Phone number: Website: https://aptose.com
Answer: Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkins lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month